SELLAS Life Sciences Group (NASDAQ:SLS - Get Free Report) issued its earnings results on Thursday. The company reported ($0.08) earnings per share for the quarter, topping analysts' consensus estimates of ($0.11) by $0.03, Zacks reports. During the same period last year, the business earned ($1.34) EPS.
SELLAS Life Sciences Group Stock Performance
Shares of SELLAS Life Sciences Group stock traded up $0.03 during trading hours on Monday, reaching $1.23. The company's stock had a trading volume of 1,239,202 shares, compared to its average volume of 1,407,748. The company has a market capitalization of $86.57 million, a P/E ratio of -1.78 and a beta of 2.43. The stock's fifty day simple moving average is $1.21 and its two-hundred day simple moving average is $1.17. SELLAS Life Sciences Group has a one year low of $0.77 and a one year high of $1.84.
About SELLAS Life Sciences Group
(
Get Free Report)
SELLAS Life Sciences Group, Inc, a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer.
Featured Articles
Before you consider SELLAS Life Sciences Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and SELLAS Life Sciences Group wasn't on the list.
While SELLAS Life Sciences Group currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
